In vivo rate-determining steps of tau seed accumulation in Alzheimer’s disease is a research paper published in Science Advances (2021). On theSindex it has a DataRank of 0. It has been cited 133 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Medical Research Council
Grant: MR/M009041/1
European Research Council
Grant: 669237
Characterising protein oligomers and their role in neurodegenerative disease in humans
NIA NIH HHS
Grant: P30 AG062421
NIA NIH HHS
Grant: RF1 AG056151
Medical Research Council
Grant: UKDRI-1015
Wellcome Trust
Grant: 103838
Restoring brain function: from cortical microcircuits to complex behaviours in neurodegenerative disease.
NIA NIH HHS
Grant: RF1 AG059789
Medical Research Council
Grant: UKDRI-2003
Wellcome Trust
Grant: 103838/Z/14/Z
NIA NIH HHS
Grant: RF1 AG063521
National Institutes of Health
Grant: 1RF1AG059789-01
Are multiple tau species toxic in Alzheimer's Disease?
National Institutes of Health
Grant: 5P30AG062421-03
Massachusetts Alzheimer's Disease Research Center
National Institutes of Health
Grant: 1RF1AG056151-01A1
Tauopathy in AD and FTD - Molecular Determinants of Phenotypic Diversity
Wellcome Trust
Fields of Study
Keywords
Sustainable Development Goals
Additional file 1 of Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer’s Disease
Additional file 1 of Pathological and neurophysiological outcomes of seeding human-derived tau pathology in the APP-KI NL-G-F and NL-NL mouse models of Alzheimer’s Disease
Additional file 1 of Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model
Additional file 1 of Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model
In vivo rate-determining steps of tau seed accumulation in Alzheimer's disease.